Drug Trial Radar · NCT05393271
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Oct 3, 2022
Primary completion
Apr 24, 2023
Study completion Apr 24, 2023
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4011499 in healthy adults. The study will be conducted in 3 parts: Part 1 will investigate single ascending doses (SAD) and Part 2 will investigate multiple ascending doses (MAD). Part 3 will investigate single dose of a new formulation of VH4011499. The transition from SAD to MAD will be based on the assessment of the Safety and Dose Escalation Committee.
Conditions
- HIV Infections
Interventions
VH4011499Drug
VH4011499 will be administered.
PlaceboDrug
Placebo will be administered.
MidazolamDrug
Midazolam will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Adverse Events (AEs)Time frame: Up to Day 28
- Part 2: Number of Participants With AEsTime frame: Up to Day 42
- Part 3: Number of Participants With AEsTime frame: Up to Day 28
- Part 1: Number of Participants With AEs by SeverityTime frame: Up to Day 28
- Part 2: Number of Participants With AEs by SeverityTime frame: Up to Day 42
- Part 3: Number of Participants With AEs by SeverityTime frame: Up to Day 28
- Part 2: Number of Participants Discontinuing Treatment Due to AEsTime frame: Up to Day 42
- Part 1: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total BilirubinTime frame: Up to Day 28
- Part 1: Absolute Values of Liver Panel Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)Time frame: Up to Day 28
- Part 2: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total BilirubinTime frame: Up to Day 42
- Part 2: Absolute Values of Liver Panel Parameters: ALT, ALP and ASTTime frame: Up to Day 42
- Part 3: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total BilirubinTime frame: Up to Day 28
- Part 3: Absolute Values of Liver Panel Parameters: ALT, ALP and ASTTime frame: Up to Day 28
- Part 1: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total BilirubinTime frame: From Baseline (Day 1) and up to Day 28
- Part 1: Change From Baseline in Liver Panel Parameters: ALT, ALP and ASTTime frame: From Baseline (Day 1) and up to Day 28
- Part 2: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total BilirubinTime frame: From Baseline (Day 1) and up to Day 42
- Part 2: Change From Baseline in Liver Panel Parameters: ALT, ALP and ASTTime frame: From Baseline (Day 1) and up to Day 42
- Part 3: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total BilirubinTime frame: From Baseline (Day 1) and up to Day 28
- Part 3: Change From Baseline in Liver Panel Parameters: ALT, ALP and ASTTime frame: From Baseline (Day 1) and up to Day 28
- Part 1: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel ParametersTime frame: Up to Day 28
- Part 2: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel ParametersTime frame: Up to Day 42
- Part 3: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel ParametersTime frame: Up to Day 28
- Part 1: Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to Infinity (0-inf) Following Single Dose Administration of VH4011499Time frame: At Day 1
- Part 2: AUC Over a Dosing Interval From Time of Dosing to the Time of the Subsequent Dose (0-t) Following Repeat Dose Administration of VH4011499Time frame: At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
- Part 1: Maximum Observed Plasma Concentration (Cmax) Following Single Dose Administration of VH4011499.Time frame: At Day 1
- Part 1: Time to Maximum Observed Plasma Concentration (Tmax) Following Single Dose Administration of VH4011499Time frame: At Day 1
- Part 1: Apparent Terminal Half-life (T1/2) Following Single Dose Administration of VH4011499Time frame: At Day 1
- Part 2: Cmax Following Repeat Dose Administration of VH4011499Time frame: At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
- Part 2: Tmax Following Repeat Dose Administration of VH4011499Time frame: At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
- Part 2: T1/2 Following Repeat Dose Administration of VH4011499Time frame: At Day 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Day 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.